Behavioral Intervention to Reduce Novel Antipsychotic Medication Health Risks

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

333

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Mental Illness
Interventions
BEHAVIORAL

Cognitive behavioral sessions

Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.

BEHAVIORAL

Time-matched attention control sessions

Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Medical College of Wisconsin

OTHER

NCT00709345 - Behavioral Intervention to Reduce Novel Antipsychotic Medication Health Risks | Biotech Hunter | Biotech Hunter